Assessment of patients with leptomeningeal metastasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to develop and validate a standardized scorecard for the neurological assessment of patients diagnosed with leptomeningeal metastases. The assessment will be utilized in both clinical trials and routine clinical practice to ensure consistent evaluation of patient conditions. By focusing on patients with confirmed or probable leptomeningeal disease, the study seeks to enhance the understanding and management of this complex condition. The study is observational and does not involve any interventional treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (18 years or more), female or male
* Histologically confirmed diagnosis of extra-CNS primary solid cancer
* Diagnosis of leptomeningeal metastases confirmed or probable per EANO ESMO criteria
* Performance status compatible with enrolment into clinical trials
* Ability to consent
* Signed informed consent form from patient
* Participation in a parallel clinical trial is allowed in this non-interventional study

Exclusion Criteria:

* Inability to give informed consent
* Inability to adhere to recommended follow-up according to the treating physician

Vulnerable participants will not be included.

Where it's running

• MD Anderson Cancer Center
  Houston, Texas, United States Recruiting
• Netherlands Cancer Institute
  Amsterdam, Netherlands Recruiting
• University Hospital Zurich
  Zurich, Switzerland Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for breast cancer patients with leptomeningeal disease

  This study is testing a new treatment combining tucatinib, capecitabine, and intrathecal trastuzumab to see if it can help people with HER2-positive metastatic breast cancer and leptomeningeal disease live longer.

  Recruiting at 10 sites Phase 2 Unicancer · Bordeaux and 10 other locations · NCT05800275

• Brain-avoiding proton craniospinal irradiation for leptomeningeal metastases

  This study tests BRAVO pCSI, a proton therapy approach that avoids certain brain regions, to see if it helps adults with leptomeningeal metastases from solid tumors.

  Recruiting University of Miami · Miami, Florida · NCT07789912

• Dendritic Cell Vaccine with HER2-targeted Therapy or Nivolumab for Breast Cancer with Leptomeningeal Metastasis

  This trial tests a dendritic cell vaccine added to trastuzumab for Her2-positive disease or to nivolumab for Her2-negative disease to see if it can be given safely to people with breast cancer that has spread to the leptomeninges.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07694986

• Optimizing gadopiclenol MRI to detect early leptomeningeal disease

  This study tests whether using gadopiclenol during brain MRI can improve early detection of leptomeningeal disease in adults with solid cancers.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07415018

• Double-dose third-generation EGFR-TKI with bevacizumab and intrathecal chemotherapy for leptomeningeal NSCLC

  This trial will try whether giving a double dose of a third-generation EGFR-TKI together with bevacizumab and spinal (intrathecal) chemotherapy can help people with EGFR-mutant NSCLC whose leptomeningeal metastasis progressed after a standard-dose third-generation EGFR-TKI.

  Recruiting Second Affiliated Hospital of Nanchang University · Nanchang, Jiangxi · NCT07398599

• B7-H3 CAR T cells for recurrent brain tumors in kids and young adults

  This early-phase trial tests a personalized CAR T-cell therapy called B7-H3 CAR T for children and young adults with recurrent or progressive brain tumors.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07390539

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.